Overview

Pragmatic Trial Comparing Weight Gain in Children With Autism Taking Risperidone Versus Aripiprazole

Status:
Recruiting
Trial end date:
2025-07-01
Target enrollment:
0
Participant gender:
All
Summary
This study aims to compare two FDA approved medications (aripiprazole and risperidone) for the treatment of behavioral dysregulation in children with autism spectrum disorders. This trial, done in the context of routine clinical care, will seek to evaluate whether aripiprazole or risperidone is associated with more weight gain in children.
Phase:
Phase 4
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Vanderbilt University Medical Center
Treatments:
Aripiprazole
Risperidone
Criteria
Inclusion Criteria:

- age 17 years and young

- diagnosed with autism

- have behavior problems

- seen in Vanderbilt clinic

- naïve to atypical antipsychotics

Exclusion Criteria:

- 18 years or older

- history of atypical antipsychotic use

- not diagnosed with autism